A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia-Reference-Cited by-同舟云学术

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

Published:1998-10 Issue:1 Volume:103 Page:100-109
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:British Journal of Haematology

Author:

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.1998.00948.x/fullpdf

Reference21 articles.

1. Secondary prevention of vascular disease by prolonged antiplatelet treatment;Antiplatelet Trialists' Collaboration;British Medical Journal,1988

2. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells;Berman;Blood,1992

3. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed AML;Berman;Blood,1991

4. Idarubicin plus cytarabine versus doxorubicin plus cytarabine in induction therapy for acute non-lymphoid leukemia: a randomized trial;Bezwoda;Leukemia and Lymphoma,1990

5. Long-term effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG;Büchner;Leukemia,1992

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal timing to retrieve oocytes for fertility preservation in patients with acute myeloid leukemia: two cases of controlled ovarian stimulation using DuoStim with a literature review;Gynecological Endocrinology;2023-06-04

2. Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023;Cancers;2023-05-31

3. Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors;Cancer Reports;2023-03-28

4. Frontline Management of Acute Myeloid Leukaemia Eligible for Intensive Chemotherapy;Pathogenesis and Treatment of Leukemia;2023

5. Prognostic Relevance of NPM1 and FLT3 Mutations in Acute Myeloid Leukaemia, Longterm Follow-Up—A Single Center Experience;Cancers;2022-09-28